Metcela is a clinical-stage biotechnology company focused on researching and developing potentially curative fibroblast-based therapies for chronic diseases with limited therapeutic options.
Metcela provides regenerative medicine for treatment of Ischemic Heart Disease.
Metcela was founded in 2016 by Takahiro Iwamiya and Kenichi Nogami. The company is headquartered in Tsuruoka-shi, Yamagata, Japan.
Metcela's mission is to provide patients with an innovative and alternative treatment option.
Metcela’s core patented technology involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast (VCF)*. VCAM-1-positive cardiac fibroblasts are known to replenish and re-establish the damaged cardiac muscles and the microenvironment surrounding them.
Metcela has been in a collaborative joint study with Japan Lifeline Co., Ltd. (JLL) and University of Tsukuba since 2018 to develop the cell therapy product MTC001, combining VCFs and a specialized catheter system for target delivery of the cells to the heart.
Metcela is backed by Japan Lifeline Co., Ltd. (JLL), Sony Innovation Fund, Tsukuba Exceed Fund (TX fund) and others. The company raised 430 million yen ($4M) in a Series B round on May 20, 2020. This brings Metcela's total funding to $8.7M to date.